Covidien-CardioDigital deal
This article was originally published in The Gray Sheet
Executive Summary
Covidien acquires signal processing technology assets from Edinburgh-based CardioDigital to be included in Covidien pulse oximeter products such as Nellcor, Covidien announced Aug. 7. Terms of the deal were not disclosed
You may also be interested in...
Covidien Aims To Breathe Life Into Respiratory Biz With Ventilation Pipeline
Covidien plans to reinvigorate its respiratory business by targeting higher-growth market segments, such as devices to combat ventilator-associated pneumonia, the company said during its Sept. 10 investor day in New York
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.